Surrey Heartlands

Joint Formulary & PAD

Budesonide - Inflammatory bowel disease

You are here : Home > Formulary Search > Budesonide - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Foam enema
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
 

Status 2

Red
Formulations :
  • Modified release capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
R
Restrictions / Comments :
Important
3mg MR capsules - gastroenterology team only
 

Status 3

See narrative
Formulations :
  • Suppositories
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD2
Restrictions / Comments :
Important

Not assessed for formulary status. Applications for formulary entry via APC.

Documentation

Guidelines (Local)
Ulcerative Colitis (Pathway 2) - Primary care - May 2018.pdf
Safety Information
Implementing-the-steroid-card-safety-advice - PrescQIPP-July-2021
Safety Information
Steroid treatment in adults - Safe Management, adrenal insufficiency, adrenal crisis - SPS 2021
Webpage
Steroid Medication Warning Cards for Children & Young People - NPPG guidance - Nov 2021

PAD Profile

ChemicalSubstance :
Budesonide
Indication :
Inflammatory bowel disease
Group Name :
Keywords :
Ulcerative colitis, UC, IBD, protitis, procto sigmoiditis, ulcerative proctitis
Brand Names Include :
Budenofalk
Important Information :
Steroid safety considerations
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Inflammatory bowel disease
Supporting Documents :
4
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Budesonide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Inflammatory bowel disease.

Committee Recommendations (3)

02 Oct 24 - Not Set

Budesonide SUPPOSITORIES: have not yet been assessed for formulary status and is not currently on the APC work-plan.

This formulation has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

07 Feb 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Please see the attached pathway which has been developed in conjunction with local specialists for the GP management of adult patients with known ulcerative colitis . 

13 Mar 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Budenofalk (budesonide) rectal foam as a treatment option for patients with active Ulcerative Colitis
Budenofalk (budesonide) rectal foam will be considered GREEN on the traffic light system
Primary care prescribers should consider switching patients to budesonide rectal foam and for all new patients to use budesonide rectal foam moving forwards.